Biotechnology APAC News & Press Release Distribution

Biotechnology

All
Global

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-11-06 09:08 1510

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

2024-11-06 08:30 1585

The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024

WASHINGTON, Nov. 1, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve Pl...

2024-11-01 21:00 1800

DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology

* Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation * Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- OnOctober 30, a Ko...

2024-11-01 21:00 3725

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

* This approval marks the second international marketing authorization for sugemalimab outside ofChina, following its recent approval by the European Commission. * The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination...

2024-10-31 13:00 2063

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...

2024-10-31 12:34 1658

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-10-30 22:24 2125

Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy

SINGAPORE, Oct. 30, 2024 /PRNewswire/ -- Teijin Limited and Hilleman Laboratories , a biotechnology company based inSingapore, announced today the signing of a Memorandum of Understanding, for the establishment of a strategic international bu...

2024-10-30 15:00 1710

Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...

2024-10-29 20:30 2220

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the ...

2024-10-29 19:27 2371

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China

YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially...

2024-10-29 12:00 1552

Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics

SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-10-29 07:57 1767

/C O R R E C T I O N -- Seegene Inc./

In the news release, Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative, issued 24-Oct-2024 by Seegene Inc. over PR Newswire, we are advised by the company that the second photo and its caption should be removed as origina...

2024-10-28 12:50 3879

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...

2024-10-25 20:30 1915

HiConf Seoul 2024 successfully wraps up, sparks up discussions for future of food tech and international partnerships

* Global food tech experts gathered to share innovative ideas, discuss market insights, and explore development potential * Abu Dhabi-based investment firm HITI partners with Dongwha Pharmaceutical to manufacture and distribute cognitive enhancement ingredients in theMiddle East * HITI join...

2024-10-25 10:39 2464

HiConf Seoul 2024 successfully wraps up, sparks up discussions for future of food tech and international partnerships

Innovation at the Forefront: Angel Yeast Shines at FHA 2024

SINGAPORE, Oct. 24, 2024 /PRNewswire/ -- The FHA 2024 exhibition in Singapore, Asia's largest food and beverage show, is taking place from October 22 to 25, and is generating significant buzz within the hospitality sector. Angel Yeast (SH600298) is showcasing its lates...

2024-10-24 20:30 5460

Innovation at the Forefront: Angel Yeast Shines at FHA 2024

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA ...

2024-10-24 10:00 2197

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation

HMI-115 has demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 50% Most of the patients reported normal menstrual periods No typical peri-menopausal symptoms were re...

2024-10-24 08:08 4053

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation

SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

* This approval paves the way for exports to the world's fourth most populous country. * SK bioscience aims to continue to grow as a global vaccine brand beyond Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience , a global innovativ...

2024-10-23 15:11 1437

SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

Australia's Healthcare Innovators in Stroke and Paediatric Care Honoured at 2024 Challenger Summit

Life sciences investor Proto Axiom awards $250,000 in prizes at inaugural Summit SYDNEY, Oct. 23, 2024 /PRNewswire/ -- The 2024 Challenger Summit concluded with two visionary researchers recognised for their groundbreaking contributions to treatment of stroke and paediatric skin care. The Summit...

2024-10-23 09:29 1453

1 ... 4 5 678 9 10 ... 180